Paper · 26923600

Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases.

Renaud JB and 18 others. Cell Rep, 2016. Cited by 247 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases. Papers, record 26923600. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26923600

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases.; PubMed
Journal: Cell Rep; PubMed
Year: 2016; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/26923600/; PubMed
DOI: https://doi.org/10.1016/j.celrep.2016.02.018; PubMed
The journal: https://conductscience.org/library/journal-index/101573691; PubMed
Citations, by iCite: 247; iCite
Relative citation ratio, by iCite: 7.31; iCite
Revised in PubMed: 2024-01-04; PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Renaud JB	Jean-Baptiste
2	Boix C	Charlotte
3	Charpentier M	Marine
4	De Cian A	Anne
5	Cochennec J	Julien
6	Duvernois-Berthet E	Evelyne
7	Perrouault L	Loïc
8	Tesson L	Laurent
9	Edouard J	Joanne
10	Thinard R	Reynald

1 to 10 of 19Source PubMed

See all 19 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
CRISPR-Cas Systems	Major topic
Endonucleases	Major topic
Gene Editing	Major topic
Transcription Activator-Like Effector Nucleases	Major topic
Animals
Base Sequence
Cell Line, Tumor
Gene Targeting
Humans
INDEL Mutation
Mice
Oligonucleotides
Rats
Zebrafish

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by188

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 247 citations.

PMID	Title	Journal	Year	In Papers	Source
42,671,510	From Design to Single-Cell Cloning: A Complete RNP-Based CRISPR-Cas9 Protocol for Precision Gene Correction in Human iPSCs.	Stem Cell Rev Rep	2026	https://conductscience.org/library/papers/42671510	PubMed
42,649,193	Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion.	Nat Commun	2026	https://conductscience.org/library/papers/42649193	PubMed
42,633,875	Site and mechanism of BK channel inhibition and cerebral artery constriction by pregnenolone.	Pharmacol Res	2026	https://conductscience.org/library/papers/42633875	PubMed
42,353,300	CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42353300	PubMed
42,239,119	A bulk cell heterozygous knock-in strategy for targeted protein degradation.	bioRxiv	2026	https://conductscience.org/library/papers/42239119	PubMed
42,230,639	Cyanine-modified ssODNs enhance CRISPR-Cas9 HDR in stem cell embryo models via chromatin and chemical modulation.	Nat Commun	2026	https://conductscience.org/library/papers/42230639	PubMed
42,113,764	Non-viral in vivo electroporation-based chromosomal engineering and repair assessment in the murine uterine epithelium.	PLoS One	2026	https://conductscience.org/library/papers/42113764	PubMed
41,840,308	CRISPR-Cas9: Genome Engineering and Future Vaccine Applications.	Mol Biotechnol	2026	https://conductscience.org/library/papers/41840308	PubMed
41,776,280	HUH-tagged Cas9 as a platform for efficient ssODN-mediated knock-in via embryo and adult injection in insects.	Commun Biol	2026	https://conductscience.org/library/papers/41776280	PubMed
41,674,724	CRISPR-MiX: A pooled single-stranded donor strategy to enhance HDR efficiency in human iPSCs.	Mol Ther Nucleic Acids	2026	https://conductscience.org/library/papers/41674724	PubMed

1 to 10 of 188

See all 188 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26923600

GET https://conductscience.org/api/papers/v1/26923600/cited_by?page=2

API reference For AI assistants